GeneDx Holdings Corp. Investors Sue Over Alleged Securities Law Violations
A lawsuit filed alleges GeneDx Holdings Corp. and its executives engaged in violations of securities laws. Investors who experienced substantial losses have an opportunity to lead the class action.
Investors who suffered significant losses in GeneDx Holdings Corp. (NASDAQ: WGS) stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to seek appointment as lead plaintiff in a class action lawsuit against the company. The lawsuit, filed in the U.S. District Court for the District of Connecticut under the name Basma v. GeneDx Holdings Corp., charges GeneDx and certain of its top executives with violations of the Securities Exchange Act of 1934.
The complaint alleges that GeneDx made false and/or misleading statements and failed to disclose significant issues with the viability of Fabric Genomics, a company specializing in AI-driven genomic interpretation. GeneDx had announced an agreement to acquire Fabric Genomics in April 2025.
The situation escalated in May 2026 when GeneDx announced its first-quarter results. The company reported a drop in adjusted gross margin from 74% to 69% and reduced earnings projections. Additionally, a $31.3 million impairment loss directly attributable to Fabric Genomics was disclosed. Following this news, GeneDx's stock price declined by over 49%.
The Private Securities Litigation Reform Act of 1995 allows any investor who purchased GeneDx common stock during the Class Period to seek appointment as lead plaintiff. The lead plaintiff directs the litigation on behalf of all class members and can select their own legal counsel.